Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351377
Status:
COMPLETED
Last Update Posted:
2011-04-21
First Post:
2006-07-10
Brief Title:
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Measurement and Analysis of Patient Reported Gastrointestinal GI and Health-related Quality of Life HRQL Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate MPA
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Treatment with the immunosuppressive drug mycophenolate mofetil MMF may result in gastrointestinal GI complications in some patients This study will 1 determine the proportion of patients with autoimmune diseases who are experiencing any GI complaints under MMF-based immunosuppressive treatment and 2 assess if a switch from MMF to enteric-coated mycophenolate sodium EC-MPS results in improved GI andor health-related quality of life outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None